About: The Natural Compound Homoharringtonine Presents Broad Antiviral Activity In Vitro and In Vivo

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Natural Compound Homoharringtonine Presents Broad Antiviral Activity In Vitro and In Vivo Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The Natural Compound Homoharringtonine Presents Broad Antiviral Activity In Vitro and In Vivo
Creator	Zhou, Lei Li, Cui-Cui Meng, Wen Wang, Xiao-Jia Dong, Hui-Jun Hu, Yan-Xin Wang, Zhao-Hua
topic	covid:7cdd0a62e95aebd067147c0fd81ec62dce46ad42#this
Source	PMC
abstract	To complement traditional antivirals, natural compounds that act via host targets and present high barriers to resistance are of increasing interest. In the work reported here, we detected that homoharringtonine (HHT) presents effective antiviral activity. HHT completely inhibited infections of vesicular stomatitis virus (VSV), Newcastle disease virus (NDV), and porcine epidemic diarrhea virus (PEDV) at concentrations of 50, 100, and 500 nM in cell cultures, respectively. Treatment with HHT at doses of 0.05 or 0.2 mg/kg significantly reduced viral load and relieved severe symptoms in PEDV- or NDV-infected animals. HHT treatment, however, moderately inhibited avian influenza virus (AIV) infection, suggesting its potent antiviral action is restricted to a number of classes of RNA viruses. In this study, we also observed that HHT actively inhibited herpes simplex virus type 1 (HSV-1) replication with a 50% inhibitory concentration (IC(50)) of 139 nM; the treatment with HHT at 1000 nM led to reductions of three orders of magnitude. Moreover, HHT antagonized the phosphorylation level of endogenous and exogenous eukaryotic initiation factor 4E (p-eIF4E), which might regulate the selective translation of specific messenger RNA (mRNA). HHT provides a starting point for further progress toward the clinical development of broad-spectrum antivirals.
has issue date	2018-11-01(xsd:dateTime)
bibo:doi	10.3390/v10110601
bibo:pmid	30388805
has license	cc-by
sha1sum (hex)	7cdd0a62e95aebd067147c0fd81ec62dce46ad42
schema:url	https://doi.org/10.3390/v10110601
resource representing a document's title	The Natural Compound Homoharringtonine Presents Broad Antiviral Activity In Vitro and In Vivo
has PubMed Central identifier	PMC6266276
has PubMed identifier	30388805
schema:publication	Viruses
resource representing a document's body	covid:7cdd0a62e95aebd067147c0fd81ec62dce46ad42#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/7cdd0a62e95aebd067147c0fd81ec62dce46ad42
is schema:about of	named entity 'ANTIVIRAL ACTIVITY' named entity 'viral load' named entity 'HHT' named entity 'animals' named entity 'regulate' named entity 'antagonized' named entity 'magnitude' named entity 'HHT' named entity 'cell cultures' named entity 'compounds' named entity 'selective' named entity 'HOMOHARRINGTONINE' named entity 'NATURAL COMPOUND' named entity 'LED' named entity 'WORK' named entity 'CONCENTRATIONS' named entity 'CELL CULTURES' named entity 'INFECTED' named entity 'RELIEVED' named entity 'HERPES SIMPLEX VIRUS TYPE 1' named entity 'SELECTIVE' named entity 'CLINICAL DEVELOPMENT' named entity 'TREATMENT' named entity '500' named entity '50%' named entity 'MESSENGER RNA' named entity 'PORCINE EPIDEMIC DIARRHEA VIRUS' named entity 'PROGRESS' named entity 'PRESENT' named entity 'CONCENTRATION' named entity 'PROVIDES' named entity 'OBSERVED' named entity 'REGULATE' named entity 'RESISTANCE' named entity 'ANIMALS' named entity 'ORDERS' named entity '1000' named entity 'NATURAL' named entity '0.2' named entity 'CLASSES' named entity 'INFECTIONS' named entity 'HIGH' named entity 'MG%' named entity 'INTEREST' named entity 'ITS' named entity 'REPLICATION' named entity '0.05' named entity 'BROAD' named entity 'PRESENTS' named entity '100%' named entity 'COMPLEMENT' named entity 'STUDY' named entity 'LEVEL' named entity 'SPECIFIC' named entity 'RESTRICTED' named entity 'INFECTION' named entity 'ACT' named entity 'EFFECTIVE' named entity 'SPECTRUM' named entity 'IN VITRO' named entity 'COMPLETELY' named entity 'IN VIVO' named entity 'INHIBITED' named entity '139' named entity 'PHOSPHORYLATION' named entity 'BROAD' named entity 'REPORTED' named entity 'NEWCASTLE DISEASE VIRUS' named entity 'ANTIVIRAL ACTIVITY' named entity 'TRADITIONAL' named entity 'AVIAN INFLUENZA VIRUS' named entity 'REDUCTIONS' named entity 'EUKARYOTIC INITIATION FACTOR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software